Statin drug interactions and related adverse reactions

被引:96
作者
Bellosta, Stefano [1 ]
Corsini, Alberto [1 ]
机构
[1] Univ Milan, Dipartimento Sci Farmacol & Biomol, I-20133 Milan, Italy
关键词
adverse drug reactions; drug-drug interactions; HMG-CoA reductase inhibitors; polypharmacy; statins; HMG-COA REDUCTASE; INCREASES SERUM CONCENTRATIONS; GRAPEFRUIT JUICE; CONCOMITANT USE; P-GLYCOPROTEIN; SEVERE RHABDOMYOLYSIS; INDUCED MYOPATHY; INTERINDIVIDUAL DIFFERENCES; MYOCARDIAL-INFARCTION; HEALTHY-VOLUNTEERS;
D O I
10.1517/14740338.2012.712959
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Statin monotherapy is generally well tolerated, with a low frequency of adverse events. The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently. Because statins are prescribed on a long-term basis, their possible interactions with other drugs deserve particular attention, as many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment. Areas covered: This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions and related adverse reactions. Expert opinion: Avoiding drug-drug interactions and consequent adverse drug reactions is essential in order to optimize compliance, and thus improve the treatment of patients at high cardiovascular risk. The different pharmacokinetic profiles among statins should be carefully considered, in order to understand the possible spectrum of drug interactions. The growing trend toward earlier statin treatment for the prevention of cardiovascular disease means that physicians must anticipate future polypharmacy when their patients require additional medications for comorbid conditions.
引用
收藏
页码:933 / 946
页数:14
相关论文
共 106 条
[1]   Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy [J].
Aberg, Judith A. .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2009, 38 (01) :207-+
[2]   Cardiovascular Complications in HIV Management: Past, Present, and Future [J].
Aberg, Judith A. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (01) :54-64
[3]   Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects [J].
Agrawal, A. R. ;
Tandon, M. ;
Sharma, P. L. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (11) :1812-1818
[4]   Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly [J].
Akao, Hironobu ;
Polisecki, Eliana ;
Kajinami, Kouji ;
Trompet, Stella ;
Robertson, Michele ;
Ford, Ian ;
Jukema, J. Wouter ;
de Craen, Anton J. M. ;
Westendorp, Rudi G. J. ;
Shepherd, James ;
Packard, Christopher ;
Buckley, Brendan M. ;
Schaefer, Ernst J. .
ATHEROSCLEROSIS, 2012, 220 (02) :413-417
[5]   Safety and Efficacy of Statin Therapy in Patients Switched From Cyclosporine A to Sirolimus After Cardiac Transplantation [J].
Aliabadi, Arezu Z. ;
Mahr, Stephane ;
Dunkler, Daniela ;
Groemmer, Martina ;
Zimpfer, Daniel ;
Wolner, Ernst ;
Grimm, Michael ;
Zuckermann, Andreas O. .
TRANSPLANTATION, 2008, 86 (12) :1771-1776
[6]   Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin [J].
Amundsen, Rune ;
Christensen, Hege ;
Zabihyan, Behnaz ;
Asberg, Anders .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (09) :1499-1504
[7]  
[Anonymous], 2010, Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications
[8]   Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial [J].
Armitage, Jane ;
Bowman, Louise ;
Wallendszus, Karl ;
Bulbulia, Richard ;
Rahimi, Kazem ;
Haynes, Richard ;
Parish, Sarah ;
Peto, Richard ;
Collins, Rory ;
Meade, T. ;
Sleight, P. ;
Collins, R. ;
Armitage, J. ;
Bowman, L. ;
Parish, S. ;
Peto, R. ;
Barton, J. ;
Bray, C. ;
Wincott, E. ;
Dayanandan, R. ;
Clarke, R. ;
Graham, I. ;
Simpson, D. ;
Warlow, C. ;
Wilken, D. ;
Tobert, J. ;
Mushner, T. ;
Doll, R. ;
Wilhelmsen, L. ;
Fox, K. ;
Hill, C. ;
Sandercock, P. ;
Webster, J. ;
Henderson, J. ;
Nixon, A. ;
Lackie, S. ;
Thompson, J. ;
Brown, M. ;
Blackwood, S. ;
Morgan, M. ;
Rhoden, W. ;
Saeed, B. ;
Houghton, M. ;
Nicholson, A. ;
Simpson, C. ;
Hoburn, B. ;
Cooper, I. ;
Gallivan, A. ;
Pickerell, E. ;
Hancock, J. .
LANCET, 2010, 376 (9753) :1658-1669
[9]   The interaction of diltiazem with lovastatin and pravastatin [J].
Azie, NE ;
Brater, DC ;
Becker, PA ;
Jones, DR ;
Hall, SD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) :369-377
[10]  
Bader T, 2012, J HEPATOL, V56, P305, DOI 10.1016/j.jhep.2011.08.016